{"pmid":32360420,"pmcid":"PMC7182527","title":"Cytokine storm intervention in the early stages of COVID-19 pneumonia.","text":["Cytokine storm intervention in the early stages of COVID-19 pneumonia.","Clinical intervention in patients with corona virus disease 2019 (COVID-19) has demonstrated a strong upregulation of cytokine production in patients who are critically ill with SARS-CoV2-induced pneumonia. In a retrospective study of 41 patients with COVID-19, most patients with SARS-CoV-2 infection developed mild symptoms, whereas some patients later developed aggravated disease symptoms, and eventually passed away because of multiple organ dysfunction syndrome (MODS), as a consequence of a severe cytokine storm. Guidelines for the diagnosis and treatment of SARS-CoV-2 infected pneumonia were first published January 30(th), 2020; these guidelines recommended for the first time that cytokine monitoring should be applied in severely ill patients to reduce pneumonia related mortality. The cytokine storm observed in COVID-19 illness is also an important component of mortality in other viral diseases, including SARS, MERS and influenza. In view of the severe morbidity and mortality of COVID-19 pneumonia, we review the current understanding of treatment of human coronavirus infections from the perspective of a dysregulated cytokine and immune response.","Cytokine Growth Factor Rev","Sun, Xinjuan","Wang, Tianyuan","Cai, Dayong","Hu, Zhiwei","Chen, Jin'an","Liao, Hui","Zhi, Liming","Wei, Hongxia","Zhang, Zhihong","Qiu, Yuying","Wang, Jing","Wang, Aiping","32360420"],"abstract":["Clinical intervention in patients with corona virus disease 2019 (COVID-19) has demonstrated a strong upregulation of cytokine production in patients who are critically ill with SARS-CoV2-induced pneumonia. In a retrospective study of 41 patients with COVID-19, most patients with SARS-CoV-2 infection developed mild symptoms, whereas some patients later developed aggravated disease symptoms, and eventually passed away because of multiple organ dysfunction syndrome (MODS), as a consequence of a severe cytokine storm. Guidelines for the diagnosis and treatment of SARS-CoV-2 infected pneumonia were first published January 30(th), 2020; these guidelines recommended for the first time that cytokine monitoring should be applied in severely ill patients to reduce pneumonia related mortality. The cytokine storm observed in COVID-19 illness is also an important component of mortality in other viral diseases, including SARS, MERS and influenza. In view of the severe morbidity and mortality of COVID-19 pneumonia, we review the current understanding of treatment of human coronavirus infections from the perspective of a dysregulated cytokine and immune response."],"journal":"Cytokine Growth Factor Rev","authors":["Sun, Xinjuan","Wang, Tianyuan","Cai, Dayong","Hu, Zhiwei","Chen, Jin'an","Liao, Hui","Zhi, Liming","Wei, Hongxia","Zhang, Zhihong","Qiu, Yuying","Wang, Jing","Wang, Aiping"],"date":"2020-05-04T11:00:00Z","year":2020,"_id":"32360420","source":"PubMed","week":"202019|May 04 - May 10","doi":"10.1016/j.cytogfr.2020.04.002","keywords":["covid-19","cytokine storm","inflammation","lung damage","sars-cov2"],"locations":["Cytokine"],"topics":["Treatment"],"weight":1,"_version_":1666138495481020416,"score":9.490897,"similar":[{"pmid":32418715,"title":"COVID-19: Pathogenesis, cytokine storm and therapeutic potential of interferons.","text":["COVID-19: Pathogenesis, cytokine storm and therapeutic potential of interferons.","The outbreak of the novel SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2) responsible for coronavirus disease 2019 (COVID-19) has developed into an unprecedented global pandemic. Clinical investigations in patients with COVID-19 has shown a strong upregulation of cytokine and interferon production in SARS-CoV2- induced pneumonia, with an associated cytokine storm syndrome. Thus, the identification of existing approved therapies with proven safety profiles to treat hyperinflammation is a critical unmet need in order to reduce COVI-19 associated mortality. To date, no specific therapeutic drugs or vaccines are available to treat COVID-19 patients. This review evaluates several options that have been proposed to control SARS-CoV2 hyperinflammation and cytokine storm, eincluding antiviral drugs, vaccines, small-molecules, monoclonal antibodies, oligonucleotides, peptides, and interferons (IFNs).","Cytokine Growth Factor Rev","Nile, Shivraj Hariram","Nile, Arti","Qiu, Jiayin","Li, Lin","Jia, Xu","Kai, Guoyin","32418715"],"abstract":["The outbreak of the novel SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2) responsible for coronavirus disease 2019 (COVID-19) has developed into an unprecedented global pandemic. Clinical investigations in patients with COVID-19 has shown a strong upregulation of cytokine and interferon production in SARS-CoV2- induced pneumonia, with an associated cytokine storm syndrome. Thus, the identification of existing approved therapies with proven safety profiles to treat hyperinflammation is a critical unmet need in order to reduce COVI-19 associated mortality. To date, no specific therapeutic drugs or vaccines are available to treat COVID-19 patients. This review evaluates several options that have been proposed to control SARS-CoV2 hyperinflammation and cytokine storm, eincluding antiviral drugs, vaccines, small-molecules, monoclonal antibodies, oligonucleotides, peptides, and interferons (IFNs)."],"journal":"Cytokine Growth Factor Rev","authors":["Nile, Shivraj Hariram","Nile, Arti","Qiu, Jiayin","Li, Lin","Jia, Xu","Kai, Guoyin"],"date":"2020-05-19T11:00:00Z","year":2020,"_id":"32418715","source":"PubMed","week":"202021|May 18 - May 24","doi":"10.1016/j.cytogfr.2020.05.002","keywords":["covid-19","coronavirus","interferons","recombinant","sars-cov-2"],"topics":["Treatment","Mechanism"],"weight":1,"_version_":1667254896669229056,"score":238.15762},{"pmid":32114747,"title":"[Advances in the research of cytokine storm mechanism induced by Corona Virus Disease 2019 and the corresponding immunotherapies].","text":["[Advances in the research of cytokine storm mechanism induced by Corona Virus Disease 2019 and the corresponding immunotherapies].","Corona Virus Disease 2019 (COVID-19) has seriously affected the treatment of patients and social stability. In the later stage of disease, some COVID-19 patients may develop into acute respiratory distress syndrome or even multiple organ failure. However, one of the most important mechanism underlying the deterioration of disease is cytokine storm. At present, some therapies such as interleukin-6 antibody blocker, stem cell therapy, and transfusion of convalescent plasma have been applied to counteract the cytokine storm and have made some progress. This article reviews the influences of cytokine storm syndrome on the COVID-19 and the corresponding immunotherapies to resist cytokine storm.","Zhonghua Shao Shang Za Zhi","Chen, C","Zhang, X R","Ju, Z Y","He, W F","32114747"],"abstract":["Corona Virus Disease 2019 (COVID-19) has seriously affected the treatment of patients and social stability. In the later stage of disease, some COVID-19 patients may develop into acute respiratory distress syndrome or even multiple organ failure. However, one of the most important mechanism underlying the deterioration of disease is cytokine storm. At present, some therapies such as interleukin-6 antibody blocker, stem cell therapy, and transfusion of convalescent plasma have been applied to counteract the cytokine storm and have made some progress. This article reviews the influences of cytokine storm syndrome on the COVID-19 and the corresponding immunotherapies to resist cytokine storm."],"journal":"Zhonghua Shao Shang Za Zhi","authors":["Chen, C","Zhang, X R","Ju, Z Y","He, W F"],"date":"2020-03-03T11:00:00Z","year":2020,"_id":"32114747","source":"PubMed","week":"202010|Mar 02 - Mar 08","doi":"10.3760/cma.j.cn501120-20200224-00088","keywords":["corona virus disease 2019","cytokine storm","cytokines","immune system","immunotherapy"],"topics":["Mechanism","Treatment"],"weight":1,"_version_":1666138490756136962,"score":222.07161},{"pmid":32431755,"pmcid":"PMC7220573","title":"The novel immunomodulatory biologic LMWF5A for pharmacological attenuation of the \"cytokine storm\" in COVID-19 patients: a hypothesis.","text":["The novel immunomodulatory biologic LMWF5A for pharmacological attenuation of the \"cytokine storm\" in COVID-19 patients: a hypothesis.","Background: A common complication of viral pulmonary infections, such as in the ongoing COVID-19 pandemic, is a phenomenon described as a \"cytokine storm\". While poorly defined, this hyperinflammatory response results in diffuse alveolar damage. The low molecular weight fraction of commercial human serum albumin (LMWF5A), a novel biologic in development for osteoarthritis, demonstrates beneficial in vitro immunomodulatory effects complimentary to addressing inflammation, thus, we hypothesize that LMWF5A could improve the clinical outcomes of COVID-19 by attenuating hyperinflammation and the potential development of a cytokine storm. Presentation of the hypothesis: A variety of human in vitro immune models indicate that LMWF5A reduces the production of pro-inflammatory cytokines implicated in cytokine storm associated with COVID-19. Furthermore, evidence suggests LMWF5A also promotes the production of mediators required for resolving inflammation and enhances the barrier function of endothelial cultures. Testing the hypothesis: A randomized controlled trial, to evaluate the safety and efficacy of nebulized LMWF5A in adults with Acute Respiratory Distress Syndrome (ARDS) secondary to COVID-19 infection, was developed and is currently under review by the Food and Drug Administration. Implications of hypothesis: If successful, this therapy may attenuate the cytokine storm observed in these patients and potentially reduce mortality, increase ventilation free days, improve oxygenation parameters and consequently lessen the burden on patients and the intensive care unit. Conclusions: In conclusion, in vitro findings suggest that the immunomodulatory effects of LMWF5A make it a viable candidate for treating cytokine storm and restoring homeostasis to the immune response in COVID-19.","Patient Saf Surg","Thomas, Gregory","Frederick, Elizabeth","Hausburg, Melissa","Goldberg, Laura","Hoke, Marshall","Roshon, Michael","Mains, Charles","Bar-Or, David","32431755"],"abstract":["Background: A common complication of viral pulmonary infections, such as in the ongoing COVID-19 pandemic, is a phenomenon described as a \"cytokine storm\". While poorly defined, this hyperinflammatory response results in diffuse alveolar damage. The low molecular weight fraction of commercial human serum albumin (LMWF5A), a novel biologic in development for osteoarthritis, demonstrates beneficial in vitro immunomodulatory effects complimentary to addressing inflammation, thus, we hypothesize that LMWF5A could improve the clinical outcomes of COVID-19 by attenuating hyperinflammation and the potential development of a cytokine storm. Presentation of the hypothesis: A variety of human in vitro immune models indicate that LMWF5A reduces the production of pro-inflammatory cytokines implicated in cytokine storm associated with COVID-19. Furthermore, evidence suggests LMWF5A also promotes the production of mediators required for resolving inflammation and enhances the barrier function of endothelial cultures. Testing the hypothesis: A randomized controlled trial, to evaluate the safety and efficacy of nebulized LMWF5A in adults with Acute Respiratory Distress Syndrome (ARDS) secondary to COVID-19 infection, was developed and is currently under review by the Food and Drug Administration. Implications of hypothesis: If successful, this therapy may attenuate the cytokine storm observed in these patients and potentially reduce mortality, increase ventilation free days, improve oxygenation parameters and consequently lessen the burden on patients and the intensive care unit. Conclusions: In conclusion, in vitro findings suggest that the immunomodulatory effects of LMWF5A make it a viable candidate for treating cytokine storm and restoring homeostasis to the immune response in COVID-19."],"journal":"Patient Saf Surg","authors":["Thomas, Gregory","Frederick, Elizabeth","Hausburg, Melissa","Goldberg, Laura","Hoke, Marshall","Roshon, Michael","Mains, Charles","Bar-Or, David"],"date":"2020-05-21T11:00:00Z","year":2020,"_id":"32431755","source":"PubMed","week":"202021|May 18 - May 24","doi":"10.1186/s13037-020-00248-4","keywords":["acute lung injury","acute respiratory distress syndrome","barrier function","covid-19","cytokine storm","lmwf5a","sars-cov-2"],"topics":["Treatment","Mechanism"],"weight":1,"_version_":1667342288238411777,"score":211.6368},{"pmid":32297995,"title":"High IL-6/IFN-gamma ratio could be associated with severe disease in COVID-19 patients.","text":["High IL-6/IFN-gamma ratio could be associated with severe disease in COVID-19 patients.","Cytokines are important mediators of the inflammatory response, and during infection with SARS-CoV-2 it has been suggested that there is a cytokine storm syndrome. In this study, a meta-analysis was performed to investigate whether the IL-6/IFN-gamma ratio can help predict clinical severity in patients with COVID-19. This article is protected by copyright. All rights reserved.","J Med Virol","Lagunas-Rangel, Francisco Alejandro","Chavez-Valencia, Venice","32297995"],"abstract":["Cytokines are important mediators of the inflammatory response, and during infection with SARS-CoV-2 it has been suggested that there is a cytokine storm syndrome. In this study, a meta-analysis was performed to investigate whether the IL-6/IFN-gamma ratio can help predict clinical severity in patients with COVID-19. This article is protected by copyright. All rights reserved."],"journal":"J Med Virol","authors":["Lagunas-Rangel, Francisco Alejandro","Chavez-Valencia, Venice"],"date":"2020-04-17T11:00:00Z","year":2020,"_id":"32297995","source":"PubMed","week":"202016|Apr 13 - Apr 19","doi":"10.1002/jmv.25900","keywords":["hyperinflammation","inflammation","interferon","interleukin","cytokine storm","lung damage"],"topics":["Diagnosis"],"weight":1,"_version_":1666138493259087873,"score":208.0688},{"pmid":32365556,"title":"Pharmacological (or Synthetic) and Nutritional Agonists of PPAR-gamma as Candidates for Cytokine Storm Modulation in COVID-19 Disease.","text":["Pharmacological (or Synthetic) and Nutritional Agonists of PPAR-gamma as Candidates for Cytokine Storm Modulation in COVID-19 Disease.","The cytokine storm is an abnormal production of inflammatory cytokines, due to the over-activation of the innate immune response. This mechanism has been recognized as a critical mediator of influenza-induced lung disease, and it could be pivotal for COVID-19 infections. Thus, an immunomodulatory approach targeting the over-production of cytokines could be proposed for viral aggressive pulmonary disease treatment. In this regard, the peroxisome proliferator-activated receptor (PPAR)-gamma, a member of the PPAR transcription factor family, could represent a potential target. Beside the well-known regulatory role on lipid and glucose metabolism, PPAR-gamma also represses the inflammatory process. Similarly, the PPAR-gamma agonist thiazolidinediones (TZDs), like pioglitazone, are anti-inflammatory drugs with ameliorating effects on severe viral pneumonia. In addition to the pharmacological agonists, also nutritional ligands of PPAR-gamma, like curcuma, lemongrass, and pomegranate, possess anti-inflammatory properties through PPAR-gamma activation. Here, we review the main synthetic and nutritional PPAR-gamma ligands, proposing a dual approach based on the strengthening of the immune system using pharmacological and dietary strategies as an attempt to prevent/treat cytokine storm in the case of coronavirus infection.","Molecules","Ciavarella, Carmen","Motta, Ilenia","Valente, Sabrina","Pasquinelli, Gianandrea","32365556"],"abstract":["The cytokine storm is an abnormal production of inflammatory cytokines, due to the over-activation of the innate immune response. This mechanism has been recognized as a critical mediator of influenza-induced lung disease, and it could be pivotal for COVID-19 infections. Thus, an immunomodulatory approach targeting the over-production of cytokines could be proposed for viral aggressive pulmonary disease treatment. In this regard, the peroxisome proliferator-activated receptor (PPAR)-gamma, a member of the PPAR transcription factor family, could represent a potential target. Beside the well-known regulatory role on lipid and glucose metabolism, PPAR-gamma also represses the inflammatory process. Similarly, the PPAR-gamma agonist thiazolidinediones (TZDs), like pioglitazone, are anti-inflammatory drugs with ameliorating effects on severe viral pneumonia. In addition to the pharmacological agonists, also nutritional ligands of PPAR-gamma, like curcuma, lemongrass, and pomegranate, possess anti-inflammatory properties through PPAR-gamma activation. Here, we review the main synthetic and nutritional PPAR-gamma ligands, proposing a dual approach based on the strengthening of the immune system using pharmacological and dietary strategies as an attempt to prevent/treat cytokine storm in the case of coronavirus infection."],"journal":"Molecules","authors":["Ciavarella, Carmen","Motta, Ilenia","Valente, Sabrina","Pasquinelli, Gianandrea"],"date":"2020-05-06T11:00:00Z","year":2020,"_id":"32365556","source":"PubMed","week":"202019|May 04 - May 10","doi":"10.3390/molecules25092076","keywords":["ppar-gamma","ppar-gamma agonists","coronavirus infection","cytokine storm","inflammation","metabolism"],"locations":["PPAR","PPAR","PPAR","PPAR","Synthetic"],"e_drugs":["Pioglitazone","Thiazolidinediones","Lipids"],"topics":["Treatment","Mechanism"],"weight":1,"_version_":1666138496289472512,"score":208.01968}]}